



CHOOSING ZYTIGA® /

ABOUT ZYTIGA® (abiraterone acetate)

Is ZYTIGA® Right for You?



ZYTIGA® Was the #1 Prescribed Oral Medication for Metastatic Castration-Resistant Prostate Cancer in 2015¹

ZYTIGA® is an oral, once-daily prescription medication used in combination with prednisone. ZYTIGA® is used to treat men with a type of prostate cancer called mCRPC (metastatic castration-resistant prostate cancer). This cancer is resistant to medical (eg, hormonal) or surgical treatments that lower testosterone and has spread to other parts of the body.


ZYTIGA® is **the first oral, once-daily medication** for mCRPC.

By choosing ZYTIGA®, you are joining the more than 80,000 men in the United States who have been prescribed ZYTIGA®.*

*Estimate is based on sales and use data from April 2011 to December 2015.

References: 1. Data on file. Janssen Biotech, Inc.





CHOOSING ZYTIGA® /

HOW ZYTIGA® WORKS


Understanding mCRPC

Before learning how treatment with ZYTIGA® works, it's helpful to understand how mCRPC affects your body.

[Watch a video about mCRPC](#)

Understanding How ZYTIGA® Works

ZYTIGA® works by interrupting the androgen-making process at an important step. It inhibits androgen at 3 sources—the testes, the adrenal glands, AND the tumor itself.



ZYTIGA® is different from some medicines that only decrease androgen production in the testes and do not affect the adrenal glands or prostate tumor tissue.


The Role of Prednisone With ZYTIGA®

While taking ZYTIGA® you will also take prednisone. Because of the way ZYTIGA® works, certain side effects may occur. **Prednisone may help decrease the occurrence and severity of these side effects.** For more information, talk to your doctor.

Take your prednisone exactly how your healthcare provider tells you. Do not stop taking your prescribed dose of ZYTIGA® or prednisone without talking to your healthcare provider first.

Hear Ron's Story

Hear patients share their experiences.



[Watch a ZYTIGA® Story](#)



CHOOSING ZYTIGA® /

RESULTS OF ZYTIGA®

Confidence in Results of ZYTIGA®

ZYTIGA® was approved by the FDA and proven effective in 2 clinical studies

In a clinical study of 1,088 men with metastatic castration-resistant prostate cancer, whose disease had progressed while on **androgen deprivation therapy (ADT)** and had not received prior chemotherapy, the results measured:

Overall Survival

How long men lived taking ZYTIGA® + prednisone vs **placebo** + prednisone

In the clinical study, certain men who had received ZYTIGA® + prednisone lived longer than men taking placebo + prednisone.

The **median overall survival** was 34.7 months for the group of men who received ZYTIGA® + prednisone vs 30.3 months for those men taking placebo + prednisone.

Please speak to your doctor about what this may mean to you.
View clinical study information on overall survival

Disease Progression

Length of time men lived without their disease getting worse or dying while taking ZYTIGA® + prednisone vs placebo + prednisone as measured by imaging studies

In the same study, at a planned analysis, fewer men had progression as measured by imaging studies in the group who received ZYTIGA® + prednisone compared to the group who had received placebo + prednisone.

- 65% (354 of 546) of men who received ZYTIGA® + prednisone had progression, as measured by imaging studies
- 71% (387 of 542) of men who received placebo + prednisone had progression, as measured by imaging studies

Please speak to your doctor about what this may mean to you.
View clinical study information on disease progression

Delay to Chemotherapy

The time to start chemotherapy in patients taking ZYTIGA® + prednisone vs placebo + prednisone as measured by imaging studies

Also in this study, the median time to starting chemotherapy for the group of men taking ZYTIGA® plus prednisone was 25.2 months compared to 16.8 months in the group taking placebo + prednisone.
View clinical study information on time to chemotherapy

Additionally, ZYTIGA® was studied in a clinical trial of over 1,000 men with metastatic castrate-resistant prostate cancer who received chemotherapy

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.